ABOUT US

AFYX THERAPEUTICALS

AFYX is a niche biopharmaceutical company established in 2024 through a merger of Lionheart ApS, Inphena ApS and AFYX Therapeutics A/S.

We are an innovative niche developer of pharmaceuticals aiming at securing treatments of diseases with unmet medical needs, such as cancer, women’s health and high-scale pain.

Our goal is to transform tomorrow’s treatment and quality of life for patients.

Our history

AFYX is based on the merger of three great and innovative companies bringing significant synergies together – the companies were:

Lionheart, a company focused on treatment of chronic and intermittent cluster headache. A dramatic a severely debilitating disease with limited treatment options available – We have patent protection for the use of ketamine as nasal administration in this indication.

AFYX Therapeutics A/S, a company based on development of a proprietary patented patch technology that sticks to wet surfaces and delivers pharmaceutical products locally where the patch is applied. Our two first projects focus on inflammatory diseases in the oral cavity – oral lichen planus – also a significant unmet medical need and precancerous stages of head and neck cancer in the mouth where we aim to develop a chemotherapy containing patch.

Inphena A/S, a company that already has commercial activities in several countries and develop repurposed existing pharmaceutical substances for new indications.

OUR FOCUS AND IMPACT

Our foucs is obsterices, niche oncology, as well as pain and addiction. 

Devestating conditions dramatically limit and impact people’s lives. We focus on creating genuinely innovative medicines by pushing the boundaries of science.

Our Research & Development, as well as reformulation of pharmaceuticals based on our patented technologies, help to improve challenging health issues. 

We believe our focus and impact will change people’s lives.

MERGING A DECADE OF INNOVATIONS

2014

A Company focused on development of a proprietary patented patch technology that sticks to wet surfaces and delivers pharmaceutical products locally where the patch is applied.

2015

A Company focused on treatment of chronic and intermittent cluster headache – We have patent protection for the use of S-ketamine as nasal administration in this indication.

2017

A Company focused on development and sales of repurposed existing pharmaceutical substances – current sales in several markets.

“We improve people's lives by transforming tomorrow's treatments!”

Dr. Claus J. Møller-San Pedro, CEO of AFYX

Send Us A Message

Headquarter

Agern Alle 24
DK-2970 Hørsholm
Denmark

Contact Us

+45 7174 7174
info@afyxtx.com